No adverse safety or virological changes 2 years following vorinostat in Hiv-infected individuals on antiretroviral therapy
AIDS(2017)
摘要
Objective: To determine the long-term effects of vorinostat on safety and virological parameters in HIV-infected individuals on suppressive antiretroviral therapy (ART). Design: Prospective longitudinal observational extended follow-up of 20 HIV-infected individuals on ART previously enrolled in a clinical trial of daily vorinostat 400mg for 14 days. Extended follow-up included visits at 6, 12, 18 and 24 months postenrolment in the initial clinical trial. Methods: Cell-associated unspliced HIV RNA, total HIV DNA and plasma HIV RNA were quantified by PCR, and CD4(+) and CD8(+) T cells quantified by flow cytometry. Changes over time in each parameter were assessed using the Wilcoxon matched pair signed-rank test and generalized estimating equations for trend modelling. Results: We recorded a total of 31 adverse events (26 grade 1 and five grade 2) in all study participants (n = 20). There were no significant changes in the number of CD4(+) or CD8(+) T cells or plasma HIVRNA over time. In 12 participants forwhombaseline samples were available, there were no significant changes in total HIV DNA, cell-associated unspliced HIV RNA, plasma RNA or CD4(+) and CD8(+) T cells at 6, 12, 18 or 24 months. Conclusion: Extended follow-up for 24 months did not reveal any long-term toxicity or changes in markers of HIV persistence or transcription in participants on ART who had received 14 days of vorinostat. Copyright (C) 2017 Wolters Kluwer Health, Inc. All rights reserved.
更多查看译文
关键词
acetylation,histone deacetylase inhibitors,HIV,HIV latency,latency reversal,vorinostat
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络